Trastuzumab halves risk of recurrence of breast cancer in some womenBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7523.986-d (Published 27 October 2005) Cite this as: BMJ 2005;331:986
- Roger Dobson
The result of three trials of trastuzumab (Herceptin) seem to show that the drug, used as adjuvant therapy after surgical treatment of primary breast cancer, halves the recurrence rate of breast cancer in certain women and reduces mortality by 33%.
Two papers published last week summarise the results of three trials—the combined results of the National Surgical Adjuvant Breast and Bowel Project trial plus the North …
Log in using your username and password
Log in through your institution
Sign up for a free trial